NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, looked at shares of Gilead Sciences (GILD - Get Report) , which continue to move higher while being surrounded by "controversy."
But Bernstein issued a report telling investors to stop with the worrying, and Cramer concurs. Competition likely won't be a problem in the immediate future and the insurance companies are going to pay.
Despite moving higher by 35% in 2014, it seems like Gilead can continue higher because it still trades at just 10 times earnings, Cramer said. Shares, near $102, are up 35% for the year to date. Biotech leaders like Gilead and Celgene (CELG) can move higher as more investors seek out growth, he added.
Must Read: 10 Stocks Carl Icahn Loves in 2014
-- Written by Bret Kenwell in Petoskey, Mich.